AstraZeneca Buys into RSV Vaccine Market with Potential $1.1B Icosavax Purchase

AstraZeneca on Monday inked a definitive acquisition agreement with vaccine developer Icosavax in a deal that could potentially reach $1.1 billion in value, as the biopharma giant targets the respiratory syncytial virus market.